ESSA Pharma Reschedules Special Meeting for Acquisition

ESSA Pharma ( (EPIX) ) just unveiled an update.

On September 10, 2025, ESSA Pharma Inc. announced the adjournment of its special meeting, initially scheduled for the same day, to September 29, 2025. The meeting aims to discuss and approve a transaction where XenoTherapeutics, a non-profit biotechnology company, will acquire all of ESSA’s outstanding common shares. The adjournment is intended to allow further discussions on the financial terms of the transaction, including cash forecasts and distribution to shareholders. The rescheduling of the meeting and the British Columbia Supreme Court hearing reflects ESSA’s ongoing negotiations to potentially revise the transaction’s financial terms, impacting the company’s future operations and stakeholder interests.

The most recent analyst rating on (EPIX) stock is a Hold with a $2.25 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.

Spark’s Take on EPIX Stock

According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.

ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.

To see Spark’s full report on EPIX stock, click here.

More about ESSA Pharma

ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.

Average Trading Volume: 5,857,436

Technical Sentiment Signal: Hold

Current Market Cap: $11.21M

For a thorough assessment of EPIX stock, go to TipRanks’ Stock Analysis page.